Journal News

Why cognition declines in Type 2 diabetes patients

Oluwadamilola “Dami” Oke
Dec. 19, 2023

For years, scientists have observed a correlation between the progression of Type 2 diabetes and the onset of cognitive impairment. A new theory about the cause of this, largely based on animal, cell and human genetics studies, implicates the cytochrome P450-soluble epoxide hydrolase, or CYP450-sEH, pathway in both Type 2 diabetes and cognitive decline.

CYP450s are enzymes that break down polyunsaturated fatty acids into epoxides, metabolites that are believed to have anti-inflammatory and cell-signaling properties. However, the sEH enzyme breaks down these epoxides into diols — molecules believed to be harmful to the cell.

The cytochrome P450 enzyme breaks down polyunsaturated fatty acids into epoxides and could have a therapeutic role in treating cognitive decline.
WIKIMEDIA COMMONS
The cytochrome P450 enzyme breaks down polyunsaturated fatty acids into epoxides and could have a therapeutic role in treating cognitive decline.

Once epoxides are broken into diols, they can interfere with other normal metabolic pathways and physiological functions. Both epoxides and diols belong to the group of lipid metabolites called oxylipins.

Researchers also have found that the implicated pathway is prevalent in patients with obesity, which made a team at the University of Toronto and Sunnybrook Research Institute curious about whether an association exists between the oxylipins derived from the CYP450-sEH pathway and the three conditions: Type 2 diabetes, cognitive impairment and obesity.

According to Natasha Anita, a Ph.D. candidate at Toronto and Sunnybrook and first author of the study, the researchers were motivated to investigate this association because they had previously found “that oxylipin levels in the blood differed between people with and without small vessel disease in the brain and that the diols were associated with poorer cognitive performance and neurodegeneration.”

Knowing that diabetes increases the risk for small vessel complications and cognitive impairment, the team hypothesized that oxylipins would also be implicated in cognitive function in Type 2 diabetes patients. A report of their work was published recently in the Journal of Lipid Research.

Excluding individuals with Type 1 diabetes and neurological diagnoses, among other criteria, the researchers recruited 108 individuals with Type 2 diabetes; 51 were obese and 57 were not obese.

Using neuropsychological and verbal tests, the team assessed cognitive function, verbal fluency and mental agility. They also assessed learning and short-term and long-term memory.

In their JLR paper, the researchers wrote that their results largely agreed with the results of earlier studies in people without Type 2 diabetes. They found that increased levels of diols were associated with poorer cognitive performance.

“This is the first study to look at oxylipins in relation to cognition in Type 2 diabetes,” Anita said. “Although diabetes is an established risk factor for Alzheimer’s disease and dementia, currently there is no specific treatment for cognitive problems in this population.”

The results from this study show the CYP450-sEH pathway to be a strong potential target for therapies.

“Our current work adds to the growing number of clinical studies examining the CYP450-sEH oxylipin pathway,” Anita said. “We are hopeful that this indicates a new pharmacological target to prevent cognitive decline in this population.”

Moving forward, Anita said the team is investigating “whether these oxylipins are associated with cognitive decline over time, and whether targeting this pathway will improve cognition in people with diabetes.”

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Oluwadamilola “Dami” Oke

Oluwadamilola “Dami” Oke is a Ph.D. candidate of biomedical engineering at the George Washington University with an interest in communication and outreach for science advancement. She is an ASBMB Today contributing writer.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Before we’ve lost what we can’t rebuild: Hope for prion disease
Feature

Before we’ve lost what we can’t rebuild: Hope for prion disease

July 15, 2025

Sonia Vallabh and Eric Minikel, a husband-and-wife team racing to cure prion disease, helped develop ION717, an antisense oligonucleotide treatment now in clinical trials. Their mission is personal — and just getting started.

Defeating deletions and duplications
News

Defeating deletions and duplications

July 11, 2025

Promising therapeutics for chromosome 15 rare neurodevelopmental disorders, including Angelman syndrome, Dup15q syndrome and Prader–Willi syndrome.

Using 'nature’s mistakes' as a window into Lafora disease
Feature

Using 'nature’s mistakes' as a window into Lafora disease

July 10, 2025

After years of heartbreak, Lafora disease families are fueling glycogen storage research breakthroughs, helping develop therapies that may treat not only Lafora but other related neurological disorders.

Cracking cancer’s code through functional connections
News

Cracking cancer’s code through functional connections

July 2, 2025

A machine learning–derived protein cofunction network is transforming how scientists understand and uncover relationships between proteins in cancer.

Gaze into the proteomics crystal ball
In-person Conference

Gaze into the proteomics crystal ball

July 1, 2025

The 15th International Symposium on Proteomics in the Life Sciences symposium will be held August 17–21 in Cambridge, Massachusetts.

Bacterial enzyme catalyzes body odor compound formation
Journal News

Bacterial enzyme catalyzes body odor compound formation

June 27, 2025

Researchers identify a skin-resident Staphylococcus hominis dipeptidase involved in creating sulfur-containing secretions. Read more about this recent Journal of Biological Chemistry paper.